Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


13th World Nephrology Conference

Dubai, UAE

Fakhriya Alalawi

Fakhriya Alalawi


Title: How to manage diabetes in dialysis patients?


Biography: Fakhriya Alalawi


How to manage diabetes in dialysis patients?

The incidence and prevalence of diabetes mellitus have grown significantly throughout the world, primarily due to the increased incidence of type 2 diabetes. This overall increase in the number of individuals with diabetes has had a major impact on development of diabetic kidney disease (DKD). Diabetic kidney disease (DKD) affects approximately 20–40 % of diabetic patients prompting to ESRD, making it one of the major and increasing global public health issues.

Managing diabetic patients on maintenance haemodialysis is challenging, as both uraemia and dialysis can complicate glycaemic control by affecting the secretion, clearance, and peripheral tissue sensitivity of insulin.  Moreover, Dialysis patients are at increased risk of hypoglycemia due to decreased clearance of insulin, poor nutritional intake; decreased hepatic gluconeogenesis and altered pharmacokinetics of glucose-lowering drugs by kidney failure while the conventional methods of glycemic monitoring (as glycated hemoglobin (HbA1c), fructoasmine, and glycated albumin) are confounded by the laboratory abnormalities and comorbidities related to ESRD.

There are a number of controversies in regards to the current management of diabetic patients maintained on hemodialysis. Generally Diabetes control should be optimized for each individual patient, in order to reduce diabetes-related complications, minimize adverse events and to increase survival rates among diabetic dialysis patients. However, the role of tight glycemic control in ameliorating the high mortality risk of diabetic dialysis patients is uncertain and does not appear to improve the outcomes in such population.

Ultimately, many glucose-lowering drugs with their active metabolites are metabolized and excreted through the kidneys; hence require dose adjustment or avoidance in dialysis patients.